Project Grant R01CA301628
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$633K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Louisiana, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $549,357 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University to conduct research on the regulation of the androgen receptor (AR) by the long non-coding RNA NXTAR in prostate cancer. The research aims to determine the mechanism of NXTAR suppression in castration-resistant prostate cancers, synthesize PSMA-targeted nanoparticles with NXTAR-N5 oligonucleotides and AR pathway inhibitors, and evaluate these...
This $564,543 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in prostate cancer. The key objectives are to:
Determine the conditions that allow engagement of the AR's growth-suppressive transcriptional programs in prostate cancer cells, which could be leveraged to inhibit tumor growth.
Establish the...
This $535,334 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research by the Albert Einstein College of Medicine to investigate the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to determine how aberrant androgen receptor activation in prostatic stromal cells, specifically those expressing the Gli1 protein, can promote the oncogenic transformation of prostate epithelial cells...
This $867,978 Project Grant awarded by the National Cancer Institute (CFDA 93.396, Cancer Biology Research) to Arma Bio Inc. supports the development of small molecule therapeutics targeting the AR-V7 splice variant of the androgen receptor for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The key products and services to be delivered under this 1-year grant include:
Medicinal chemistry efforts to optimize lead compounds for selectivity, potency, and mechanism of...
This federal Project Grant award, valued at $415,902 and issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research aimed at overcoming therapy resistance and lineage plasticity in castration-resistant prostate cancer. The award to the University of Massachusetts Boston will fund investigations into how the transcription factor FOXA2, in collaboration with AP-1, drives prostate cancer cells into an adaptive multilineage...
This Federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $400,000 to Nuago Therapeutics Inc. to develop an RNA interference-based therapeutic for prostate cancer. The funding will support preclinical research and development of the "NU002" therapy, which consists of short interfering RNA molecules targeting genes essential for cancer cell survival. The research aims to evaluate the uptake and...
This federal Project Grant award, totaling $1,223,742.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The primary awardee is Yale University, which is conducting research to unveil the role of the UBE2J1 enzyme in regulating androgen receptor (AR) degradation and its impact on prostate cancer (PCA) therapy resistance.
The key objectives of this 5-year project are to: 1) comprehensively analyze the role of UBE2J1...
This federal Project Grant award, R01CA291963, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award, totaling $606,869, will support research by Case Western Reserve University to investigate mechanisms of androgen receptor inverse agonists in advanced prostate cancer. Specifically, the project aims to map the epigenetic mechanisms underlying metastatic castration-resistant prostate cancer, and to explore the therapeutic...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) totaling $116,720 will fund research to investigate the molecular mechanisms underlying the interaction between the proteins ABI1 and the androgen receptor (AR). The award recipient, The Research Foundation for the State University of New York, will use advanced biophysical techniques to characterize how ABI1 binds to DNA and how its interactions with AR impact DNA binding....
This $553,550 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cedars-Sinai Medical Center aims to better understand a novel signaling axis in prostate cancer that contributes to resistance to androgen receptor signaling inhibitors (ARSIs). The study will test the hypothesis that inhibiting the CD105 protein, which mediates ARSI resistance through various mechanisms, can re-sensitize prostate cancer patients to ARSI treatment when combined...